Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor

Background:Low baseline prognostic nutritional index (PNI) scores are associated with poor survival for various malignancies; however, they vary based on the cohort and time resulting in inaccurate results. We determined the predictive value of the PNI score variations in addition to the baseline PNI scores for patients with advanced non-small cell lung cancer (NSCLC) who received programmed cell death protein 1 (PD-1) inhibitor. Methods:We retrospectively analysed 115 patients with advanced NSCLC who received PD-1 inhibitor. The median follow-up period was 28 months. Patients were clustered into four groups based on the combined PNI scores (combination of baseline and variation of PNI scores): Delta PNI-L-L, Delta PNI-L-H, Delta PNI-H-L, and Delta PNI-H-H subgroups. For instance, if PNI scores of patients with high baseline PNI score increased from baseline to 6 weeks after treatment, they were included in the Delta PNI-H-H subgroup. Cox regression models were used to identify the factors associated with survival. Results:The baseline PNI score was only related to the overall survival (OS) (P = .026), and not to the overall response rate (ORR) (P = .299) and progression-free survival (PFS) (P = .207). The ORR was associated with the combined PNI scores (P = .017). A multivariable Cox regression analysis confirmed that the combined PNI scores were independent factors for PFS (Delta PNI-L-H, 12 months, hazard ratio [HR] = 0.449, P = .009; Delta PNI-H-L, 14 months, HR = 0.500, P = .019; and Delta PNI-H-H, 17 months, HR = 0.390, P = .012; vs Delta PNI-L-L, 8 months) and OS (Delta PNI-L-H, 27 months, HR = 0.403, P = .019; Delta PNI-H-L, 28 months, HR = 0.369, P = .010; and Delta PNI-H-H, not reached, HR = 0.087, P = .002; vs Delta PNI-L-L, 15 months). Conclusions:Patients with high baseline PNI and increased PNI score had the better survival outcome. On dynamic monitoring and comprehensive assessment, the combined PNI scores significantly enhanced the survival predictive ability of patients with NSCLC treated with PD-1 inhibitor.